

The Neuronal Adaptor Protein X11 α Reduces A β Levels in the Brains of Alzheimer's APPswe Tg2576 Transgenic Mice*

Received for publication, January 16, 2003, and in revised form, September 11, 2003
Published, JBC Papers in Press, September 11, 2003, DOI 10.1074/jbc.M300503200

Ju-Hyun Lee $\ddagger$ §, Kwok-Fai Lau $\ddagger$ §, Michael S. Perkinson $\ddagger$, Claire L. Standen $\ddagger$,
Stephen J. A. Shemilt $\ddagger$, Luc Mercken $\P$, Jonathan D. Cooper $\ddagger$, Declan M. McLoughlin $\ddagger$,
and Christopher C. J. Miller $\ddagger$ ||

From the $\ddagger$ Department of Neuroscience and Section of Old Age Psychiatry, The Institute of Psychiatry, Kings College, London SE5 8AF, United Kingdom and $\P$ Aventis Pharma, Paris 94403, France

Increased production and deposition of the 40–42-amino acid β -amyloid peptide (A β) is believed to be central to the pathogenesis of Alzheimer's disease. A β is derived from the amyloid precursor protein (APP), but the mechanisms that regulate APP processing to produce A β are not fully understood. X11 α (also known as munc-18-interacting protein-1 (Mint1)) is a neuronal adaptor protein that binds APP and modulates APP processing in transfected non-neuronal cells. To investigate the *in vivo* effect of X11 α on A β production in the brain, we created transgenic mice that overexpress X11 α and crossed these with transgenics harboring a familial Alzheimer's disease mutant APP that produces increased levels of A β (APPswe Tg2576 mice). Analyses of A β levels in the offspring generated from two separate X11 α founder mice revealed a significant, approximate 20% decrease in A β (1–40) in double transgenic mice expressing APPswe/X11 α compared with APPswe mice. At a key time point in A β plaque deposition (8 months old), the number of A β plaques was also decreased in APPswe/X11 α mice. Thus, we report here the first demonstration that X11 α inhibits A β production and deposition *in vivo* in the brain.

One pathological hallmark of Alzheimer's disease is deposition of the 40–42-amino acid β -amyloid peptide (A β)¹ within the brains of affected individuals. A β is derived by proteolytic cleavage from the amyloid precursor protein (APP). APP is a type-1 membrane-spanning protein that contains a large ectodomain and a smaller, intracellular endodomain, and A β is derived from sequences that encompass parts of both ecto- and trans-membrane domains. Aberrant APP processing/metabolism leading to increased production and deposition of A β is believed to be central to the pathogenesis of Alzheimer's disease (for reviews see Refs. 1 and 2).

A number of proteins have now been shown to interact with the APP endodomain, including a variety of phosphotyrosine-

binding domain proteins (3, 4). These phosphotyrosine-binding domain proteins comprise the Fe65 and X11 families. Disabled and JNK-interacting proteins and their interactions are mediated via the phosphotyrosine-binding domains and sequences surrounding the YENPTY motif in APP (5–18).

One such protein is the neuronal adaptor X11 α , which contains a single, centrally located phosphotyrosine-binding domain through which it binds APP. However, X11 α also contains a number of other protein-protein interaction domains and via these domains mediates the assembly of multi-protein complexes. Aside from APP family members, X11 α -binding partners identified to date include CASK, munc-18, spinophilin/neurabin, neurexins, the N-type Ca²⁺ channel pore-forming α_{1B} subunit, the kinesin superfamily motor protein KIF17, presenilin 1, and the copper chaperone for superoxide dismutase-1 (19–30).

The binding of X11 α to APP has now been shown to inhibit A β production in transfected non-neuronal cells, although the mechanisms that underlie this effect are not known (16, 31–33). However, whether it fulfills similar functions *in vivo* within the brain has not so far been established. This is an important omission because there is evidence that neurons can process APP differently to cell lines in culture (34–37). Here, we have utilized transgenic mice to investigate the effects of X11 α on APP processing and demonstrate that X11 α reduces A β levels in the brain.

EXPERIMENTAL PROCEDURES

Construction of Transgenic Mice—A carboxyl-terminal Myc-tagged full-length human X11 α cDNA (28, 29) was inserted as a XhoI-SalI fragment into a modified mouse prion gene in which the single exon encoding the prion protein was deleted and engineered to contain a unique XhoI site (38). Vector sequences were removed, and the construct was injected into C57Bl6/SJL embryos (Xenogen Bioscience USA). Founder mice were crossed with C57Bl6 animals and offspring backcrossed a further three times onto this background prior to analyses. APPswe Tg2576 mice (39) were obtained from Taconic (New York) and bred by mating male mice with C57Bl6/SJL F1 females as recommended by the suppliers and as described by others (40). For crossing of X11 α and APPswe lines, male APPswe Tg2576 animals were mated with female X11 α mice.

Northern Analyses—Mouse brains were removed and bisected along the midline. One half was utilized for analyses of mRNA/protein expression (see below), and the other half was used for A β assays. RNA was prepared using Trizol reagent (Invitrogen) according to the manufacturer's instructions. RNA samples were quantified by spectrophotometric analysis, and their integrity was confirmed by observing 28 and 18 S ribosomal species following electrophoresis in denaturing 1% agarose gels in MOPS buffer (40 mM MOPS, 10 mM sodium acetate, 1 mM EDTA, pH 7.2) containing 2% formaldehyde. For Northern blotting, 20 μ g of each sample were separated as above and transferred to Gene-Screen Plus membranes (PerkinElmer Life Sciences). The probes were labeled with [γ -³²P]dCTP by random priming using a Prime-It II kit (Stratagene). APP mRNA was detected using a full-length human APP

* This work was supported by grants from the European Union Vth Framework, Wellcome Trust, Medical Research Council, Research into Aging, Croucher Foundation, and the Natalie Fund. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ These authors contributed equally to this work.

|| To whom correspondence should be addressed: Dept. of Neuroscience, P.O. Box P037, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK. Tel.: 44-207-8480393; Fax: 44-207-7080017; E-mail: chris.miller@iop.kcl.ac.uk.

¹ The abbreviations used are: A β , β -amyloid peptide; APP, amyloid precursor protein; MOPS, 3-(N-morpholino)propanesulfonic acid; TBS, Tris-buffered saline; ELISA, enzyme-linked immunosorbent assay.

cDNA probe, and β -actin was detected with a commercial probe (Clontech). Hybridizations washings and autoradiography were performed as previously described (41).

SDS-PAGE and Immunoblotting—Mouse brains were weighed and prepared as 10% (w/v) homogenate in ice-cold 125 mM Tris-Cl (pH 6.8), 5 mM EDTA, 5 mM EGTA plus complete protease inhibitor mixture (Roche Applied Science). One-quarter volume of 10% SDS sample buffer was then added, and the samples were heated in a boiling water bath for 10 min. Protein concentrations were determined using Markwell assays. The samples were separated on 8% (w/v) acrylamide gels and transferred to Protran nitrocellulose membranes (Schleicher & Schuell) using a Bio-Rad TransBlot system. The blots were probed with primary antibodies, washed in phosphate-buffered saline, and incubated with horseradish peroxidase-conjugated anti-mouse or anti-rabbit Igs (Amersham Biosciences). The blots were developed using an enhanced chemiluminescence system (Amersham Biosciences) according to the manufacturer's instructions. X11 α was detected using a rabbit polyclonal antibody (28) or mouse monoclonal antibody 9B11 (Cell Signaling) to the Myc tag on the carboxyl terminus of transgenic X11 α . APP was detected using a rabbit polyclonal antibody generated using a synthetic peptide to the last 21 amino acid residues of APP (28).

To calculate the relative amounts of APP in the different mouse brain samples, increasing amounts (2.5–40 μ g) of total brain proteins were probed for APP on immunoblots, and the signals were then quantified by pixel densitometry using a Bio-Rad GS710 imaging densitometer and Quantity 1 software as described (42). From these data, standard curves were generated so as to demonstrate that the protein amounts loaded on the gels gave APP signals on the immunoblots that were within the linear range.

Immunohistochemical Analyses—Transgenic X11 α distribution was analyzed by immunostaining for the Myc tag using antibody 9B11. Brains from 10–12-week-old X11 α transgenic and nontransgenic mice were fixed in freshly prepared 4% paraformaldehyde in phosphate-buffered saline (pH 7.4) and then cryoprotected at 4 °C in a solution of 30% sucrose in Tris-buffered saline (TBS; 40 mM Tris, 0.7% NaCl in 10 mM phosphate buffer, pH 7.8) containing 0.05% sodium azide prior to freezing on dry ice and storage at –80 °C. 40- μ m frozen sections were cut coronally or sagittally from either hemisphere, collected in TBS-azide buffer, and stored at 4 °C prior to immunohistochemical staining. The optimal concentrations of primary and secondary antisera were determined by performing a checkerboard titration on transgenic tissue. The sections were labeled by blocking endogenous peroxidase activity with 1% H₂O₂ in TBS for 15 min and then blocking with 15% normal goat serum. The sections were then incubated with antibody 9B11 diluted 1:5000 in TBS-T (TBS containing 0.3% Triton X-100) with 10% normal goat serum for 16 h at 4 °C, washed in TBS-T, and then incubated with biotinylated goat anti-rabbit Igs (Vector Laboratories) diluted in TBS-T/10% normal goat serum. Following washing in TBS, the sections were further incubated for 2 h in avidin-biotin-peroxidase complex in TBS (Vectastain, Vector Laboratories), washed in TBS, and developed with 0.05% diaminobenzidine tetrahydrochloride and 0.001% H₂O₂ in TBS. The sections were mounted on gelatin-chrome alum-coated Superfrost slides, air-dried overnight, cleared in xylene, and coverslipped with DPX (Merck).

To detect A β deposits, the brains were fixed as above, embedded in paraffin wax, and stained as described previously using antibody 1E8 that detects residues 13–27 of A β (43). Briefly, 10- μ m coronal sections through the cortex and hippocampus of APP^{swe} and APP^{swe}/X11 α double transgenic mice were deparaffinized, rehydrated, and then treated with 85% formic acid for 8 min. Following washes and incubation with primary and secondary antibodies, reactivity was developed with Vectastain Elite ABC solution (Vector Laboratories) and diaminobenzidine tetrahydrochloride with nickel enhancement, and the sections were dehydrated and mounted in DPX.

The images were captured on a Zeiss AxioScope 2 MOT using an Axiocam and Axiovision software (Zeiss). The diameters of plaques were determined using Metamorph image analysis software.

A β Assays—A β species were assayed using commercial ELISA assay kits. A β (1–40) was assayed using human amyloid β (1–40)-(N) ELISA (IBL, Hamburg, Germany) and A β (1–42) detected using Innostest β -amyloid_(1–42) ELISA (Innogenetics, Ghent, Belgium). Brain samples were prepared for assay by homogenization as 20% homogenates using a Dounce homogenizer as described (44). The protein concentrations were determined using Bradford assays. The data were analyzed by one-way analysis of variance tests.




FIG. 1. Expression of X11 α in transgenic mouse tissues. Immunoblots with antibodies to X11 α (upper panel) and 9B11 to the Myc tag (lower panel) reveal that transgene-derived X11 α is expressed principally in the brain. The transgenic X11 α migrates slightly slower than endogenous mouse X11 α because of the Myc tag. Samples from X11 α transgenic lines 10 and 15 are shown. 15 μ g of protein is loaded in each track.

RESULTS

We created X11 α transgenic mice using the mouse prion gene promoter and regulatory elements to drive expression as previously described for other genes (38). To facilitate detection of transgene-derived X11 α , we placed a Myc epitope tag on the carboxyl terminus of the protein. We obtained five transgenic founders, were able to breed from four of these, and selected the two highest level expressors as determined by immunoblot analyses (lines 10 and 15) for further study. Immunoblotting with an X11 α antibody and antibody 9B11 to the Myc tag revealed that transgenic X11 α protein was expressed principally in the brain, which is in agreement with previous studies that have utilized the prion promoter (38) (Fig. 1). Comparisons of X11 α expression in the brains of transgenic and nontransgenic littermate mice by densitometric analyses of immunoblots revealed that X11 α was overexpressed ~8-fold in line 10 and 6-fold in line 15 (Fig. 2A).

To analyze transgenic X11 α expression in more detail, we immunostained sections of transgenic and nontransgenic mouse brains with antibody 9B11 to the Myc tag. These studies revealed that transgenic X11 α protein was distributed in a similar, if not identical fashion in both transgenic lines where Myc immunoreactivity was present in neurons in a diverse number of brain regions including the cortex, hippocampus, and scattered subcortical nuclei but with no obvious expression in cells with glial morphology (Fig. 3). Myc immunoreactivity was present in apical dendrites in the cortex and hippocampus but was particularly prominent in neuronal cell bodies and proximal dendrites, and this is in agreement with studies of endogenous X11 α subcellular distribution where it has been shown to be enriched in the *trans*-Golgi network; APP is also located in these regions (30, 45). Thus, transgenic X11 α expression broadly mimics that of the endogenous protein.

To investigate the effect of X11 α overexpression on APP and A β production in the brain, we crossed each of the selected X11 α transgenic lines with transgenic mice expressing a familial Alzheimer's disease mutant APP harboring the double K670N/M671L Swedish mutation (transgenic APP^{swe} mice line Tg2576). These APP^{swe} mice secrete increased levels of human A β (1–40) and A β (1–42) (39). This approach of crossing Alzheimer's disease mutant APP mice with other transgenics to investigate the effect of a particular transgene on A β production has now been utilized in a number of studies. These include investigating the effects of wild-type and mutant presenilin 1 and β -secretase on A β production (38, 46–49) (see reviews in Refs. 50 and 51). Analyses of the offspring derived from these crosses revealed that their genotypes approximated that expected of Mendelian inheritance (one-quarter each nontransgenic, APP^{swe} transgenic, X11 α transgenic, and APP^{swe}/X11 α double transgenic). There was no evidence of any gross abnormal phenotype in any of the mice.




FIG. 2. Expression of X11 α and APP protein in the brains of mice derived from crosses between APP^{swe} Tg2576 mice and X11 α lines 10 and 15 mice. A shows immunoblots of two animals of each genotype probed with an antibody to X11 α , antibody 9B11 to the Myc tag on transgenic X11 α , and an antibody to APP as indicated. 10 μ g of protein is loaded in each track. Samples from other mice were also analyzed and produced identical results; all of the animals assayed for A β were probed for APP. B, quantification of APP signal on immunoblots of total protein from the brains of APP^{swe} Tg2576 mice. Non-Tg, nontransgenic.




FIG. 3. Histological detection of transgene-derived X11 α in transgenic mice. Transgenic X11 α was detected using monoclonal antibody 9B11 to the Myc tag. A shows labeling of the cortex of a nontransgenic mouse; B shows labeling of the same region of an X11 α transgenic mouse. Myc immunoreactive neurons were present in laminae III and V of somatosensory cortex of transgenic mice, with prominent staining of the soma and apical dendrites. Myc immunoreactive neurons (cell bodies and dendrites) were also present in the hippocampus of transgenic mice (C). Scale bar, 50 μ m.

Northern blots demonstrated that overexpression of X11 α had no detectable effect on the steady-state levels of either endogenous mouse or transgenic human APP mRNAs (Fig. 4). To determine whether overexpression of X11 α influenced APP holoprotein levels, we performed quantitative immunoblots for APP on the different brain samples. We first generated standard curves for APP signal on the blots (Fig. 2B) and, by loading amounts of protein (10 μ g) that fell within the linear range for this signal, analyzed the relative APP levels in the different mice generated from the various crosses. Statistical analyses of these data by one-way analysis of variance tests revealed that X11 α had no effect on the steady-state levels of either endogenous mouse or transgenic human APP protein (all data not shown but see Fig. 2A for examples of signals obtained from nontransgenic, APP^{swe}, X11 α , and APP^{swe}/X11 α transgenic mice).

We next compared the levels of human A β (1–40) and A β (1–




FIG. 4. Northern analyses of APP mRNAs in the brains of mice derived from crosses between APP^{swe} Tg2576 mice and X11 α lines 10 and 15 mice. APP mRNA is greatly overexpressed in the APP^{swe} mice, which makes simultaneous detection of endogenous and transgenic mRNAs difficult because of their similar electrophoretic mobilities. Two different exposures of the relevant portions of the blot are thus shown. Samples from two animals of each genotype are shown, but samples from other mice were also analyzed and produced identical results. The bottom panel shows β -actin mRNA to demonstrate equal loading of the gel. Non-Tg, nontransgenic.

42) in the brains of APP^{swe} and APP^{swe}/X11 α double transgenic mice aged between 10 and 12 weeks. For X11 α line 10 transgenic crosses, we observed a significant, 24% reduction in A β (1–40) levels in APP^{swe}/X11 α double transgenics compared with APP^{swe} only littermates ($p = 0.0015$). For X11 α line 15 transgenic crosses, we again observed a significant 17% reduction in A β (1–40) levels in APP^{swe}/X11 α double transgenics compared with APP^{swe} littermates ($p = 0.0331$) (Fig. 5). The more marked reduction of A β (1–40) levels in X11 α line 10 is consistent with the higher levels of X11 α protein detected in these animals. Analyses of A β (1–42) levels in the mice revealed no significant differences between any genotypes. Thus, overexpression of X11 α reduces A β (1–40) but not A β (1–42) levels in the brains of the APP^{swe} Tg2576 transgenic mice, and this effect is not mediated via a detectable effect on the steady-state levels of APP mRNA or protein.

Finally, we analyzed A β deposition in the brains of APP^{swe} and APP^{swe}/X11 α double transgenic mice. For these experiments we focused on transgenic line 10, which expressed the highest level of X11 α . At 7–8 months of age, APP^{swe} Tg2576 develop A β plaque deposits similar to those seen in Alzheimer's disease (40). Because this age is a key time point in the development of Alzheimer's pathology, we analyzed 8-month-old animals. Coronal sections through the cortex and hippocampus of APP^{swe} and APP^{swe}/X11 α double transgenic mice were labeled for A β deposits using antibody 1E8, and the number of plaques/section was counted. Statistical analyses of these data revealed a significant reduction in the number of A β plaques in the APP^{swe}/X11 α double transgenic mice (Fig. 6). We also compared the size of plaques in APP^{swe} and APP^{swe}/X11 α double transgenic mice and discovered that the mean diameter of plaques was reduced in the APP^{swe}/X11 α animals (mean diameter of plaques in APP^{swe} mice, 28.3 μ m; mean diameter of plaques in APP^{swe}/X11 α mice, 15.5 μ m). Statistical analyses of these data revealed a significant difference ($p = 0.027$ by one-way analysis of variance test). Thus, the number and size of amyloid plaques in the cortex/hippocampus are reduced in APP^{swe}/X11 α mice.

DISCUSSION

The X11s are a family of adaptor proteins comprising three members, X11 α , X11 β , and X11 γ , all of which bind to the carboxyl terminus of APP (6–8, 10, 12, 13, 16, 52). X11 α and X11 β are neuron-specific, whereas X11 γ is ubiquitously ex-





FIG. 5. A β levels in the brains of mice derived from crosses between APP_{swe} Tg2576 mice and X11 α lines 10 and 15 mice. Assays were performed on 11 APP_{swe} and 13 APP_{swe}/X11 α (line 10 crosses) and 13 APP_{swe} and 15 APP_{swe}/X11 α (line 15 crosses). All of the mice analyzed were aged between 10 and 12 weeks. A β (1–40) levels are reduced by 23.6% in X11 α line 10 mice ($p = 0.0015$) and by 16.7% in X11 α line 15 mice ($p = 0.0331$). Pooling data from both X11 α line 10 and 15 mice also demonstrated a significant reduction in A β (1–40) levels ($p = 0.0008$). No significant differences in A β (1–42) levels were seen in X11 α line 10 or 15 mice nor in data obtained from pooling of figures. The error bars indicate the S.E. The mouse to mouse variation in A β levels between mice of the same genotype was less than 17%. Normalizing A β levels to relative APP holoprotein levels did not significantly alter the results.

pressed (13, 21–23, 41, 52). Both X11 α and X11 β have now been shown to stabilize APP and inhibit A β secretion in transfected cells (13, 16, 31, 32, 41), although there is currently no evidence to demonstrate that any X11 protein modulates APP processing and A β secretion *in vivo* in the brain. Here, we demonstrate that overexpression of X11 α reduces A β levels and A β plaque numbers in the brains of APP_{swe} transgenic mice.

Our analyses revealed that whereas A β (1–40) levels were significantly reduced in APP_{swe}/X11 α mice, we observed no such changes in A β (1–42) levels. Whether this remains the case in older mice in which A β (1–42) levels are 1000-fold higher (40) will require analyses of aged animals. Alternatively, X11 α may have a selective effect on A β (1–40) production at all ages because the related X11 β has been shown to inhibit secretion of A β (1–40) but not A β (1–42) in transfected cells (13). However, it is notable that even in the relatively young animals analyzed here, we see a marked reduction by ~20% in the levels of A β (1–40), and this is sufficient to reduce the number of A β plaques that are deposited in 8-month-old APP_{swe}/X11 α mice. This reduction in A β plaque numbers was more marked than the 24% reduction in A β (1–40) levels would predict, and this might suggest that overexpression of X11 α acts to delay A β deposition. Indeed, the age at which A β deposition was analyzed (8 months) is a key time point in the development of Alzheimer's disease pathology in the APP_{swe} Tg2576 model and one where A β plaque deposits are first observed (40). In a contrasting fashion, crossing of APP_{swe} Tg2576 mice with Alzheimer's disease mutant presenilin 1 transgenics accelerates A β plaque formation at this age (46, 49). Thus, it will therefore be interesting to examine A β deposition in older and aged APP_{swe}/X11 α mice so as to establish the full profile of pathological changes. Additionally, because APP_{swe} mice display spatial memory deficits

(A)



(B)




FIG. 6. A β plaque deposition in the brains of mice derived from crosses between APP_{swe} Tg2576 mice and X11 α line 10 mice. A shows the number of A β plaques in APP_{swe} and APP_{swe}/X11 α mice ($n = 4$). The data were obtained from 27 coronal sections from each mouse cut through the cortex/hippocampal regions. Every tenth section was analyzed so each section was separated from its neighbor by ~100 μ m. A β plaque numbers were significantly fewer in APP_{swe}/X11 α compared with APP_{swe} mice ($p < 0.001$ analyzed by one-way analysis of variance test). The error bars indicate the S.E. B shows A β plaques in APP_{swe} and APP_{swe}/X11 α mice. Scale bar, 100 μ m.

(39, 53), it will be important to examine whether overexpression of X11 α also reduces A β -associated cognitive changes by appropriate behavioral experimentation.

The mechanisms by which X11 α inhibits A β production are not clear. In cell transfection studies, overexpression of X11 α is accompanied by increased stability of full-length APP (16, 31–33), but we did not detect any changes in APP mRNA or protein levels in the presence of X11 α in our transgenic mice. However, these effects of X11 α on APP in the highly overexpressing transfected cells are more marked than those in our transgenic lines (e.g. A β production is decreased by ~70% in one study (31). In this context, it is notable that modulating presenilin 1 expression in transgenic mice alters A β production without a detectable effect on APP levels (54, 55).

Presenilin 1 is required for the proteolytic processing of APP to release A β (54, 56–59). Interestingly, we have demonstrated that X11 α binds to presenilin 1 via its PDZ domains to facilitate the formation of APP-X11 α -presenilin 1 trimeric complexes (28), and this interaction has now been confirmed by others (30). X11 α may therefore modulate APP processing and A β production via some effect on presenilin 1 that inhibits γ -secretase activity.

Whatever the precise mechanisms by which X11 α influences APP processing, our results demonstrate that altering its expression can reduce A β levels *in vivo* in the brain. As such, modulation of X11 α function may represent a novel therapeutic strategy for Alzheimer's disease.

REFERENCES

- Selkoe, D. J. (2001) *Physiol. Rev.* **81**, 741–766
- Hardy, J., and Selkoe, D. J. (2002) *Science* **297**, 353–356
- Russo, T., Faraonio, R., Minopoli, G., De Candia, P., De Renzis, S., and Zambrano, N. (1998) *FEBS Lett.* **434**, 1–7
- Van Gassen, G., Annaert, W., and Van Broeckhoven, C. (2000) *Neurobiol. Dis.* **6**, 135–151
- Fiore, F., Zambrano, N., Minopoli, G., Donini, V., Duilio, A., and Russo, T.

- (1995) *J. Biol. Chem.* **270**, 30853–30856
6. McLoughlin, D. M., and Miller, C. C. J. (1996) *FEBS Lett.* **397**, 197–200
 7. Bressler, S. L., Gray, M. D., Sopher, B. L., Hu, Q. B., Hearn, M. G., Pham, D. G., Dinulos, M. B., Fukuchi, K. I., Sisodia, S. S., Miller, M. A., Distèche, C. M., and Martin, G. M. (1996) *Hum. Mol. Genet.* **5**, 1589–1598
 8. Borg, J.-P., Ooi, J., Levy, E., and Margolis, B. (1996) *Mol. Cell Biol.* **16**, 6229–6241
 9. Zambrano, N., Buxbaum, J. D., Minopoli, G., Fiore, F., De Candia, P., De Renzis, S., Faraonio, R., Sabo, S., Cheetham, J., Sudol, M., and Russo, T. (1997) *J. Biol. Chem.* **272**, 6399–6405
 10. Zhang, Z., Lee, C.-H., Mandiyan, V., Borg, J.-P., Margolis, B., Schlessinger, J., and Kuriyan, J. (1997) *EMBO J.* **16**, 6141–6150
 11. Duilio, A., Faraonio, R., Minopoli, G., Zambrano, N., and Russo, T. (1998) *Biochem. J.* **330**, 513–519
 12. Trommsdorff, M., Borg, J.-P., Margolis, B., and Herz, J. (1998) *J. Biol. Chem.* **273**, 33556–33560
 13. Tomita, S., Ozaki, T., Taru, H., Oguchi, S., Takeda, S., Yagi, Y., Sakiyama, S., Kirino, Y., and Suzuki, T. (1999) *J. Biol. Chem.* **274**, 2243–2254
 14. Howell, B. W., Lanier, L. M., Frank, R., Gertler, F. B., and Cooper, J. A. (1999) *Mol. Cell Biol.* **19**, 5179–5188
 15. Matsuda, S., Yasukawa, T., Homma, Y., Ito, Y., Niikura, T., Hiraki, T., Hira, S., Ohno, S., Kita, Y., Kawasumi, M., Kouyama, K., Yamamoto, T., Kyriakis, J. M., and Nishimoto, I. (2001) *J. Neurosci.* **21**, 6597–6607
 16. Mueller, H. T., Borg, J. P., Margolis, B., and Turner, R. S. (2000) *J. Biol. Chem.* **275**, 39302–39306
 17. Taru, H., Iijima, K., Hase, M., Kirino, Y., Yagi, Y., and Suzuki, T. (2002) *J. Biol. Chem.* **277**, 20070–20078
 18. Guénette, S. Y., Chen, J., Jondro, P. D., and Tanzi, R. E. (1996) *Proc. Natl. Acad. Sci. U. S. A.* **93**, 10832–10837
 19. Butz, S., Okamoto, M., and Sudhof, T. C. (1998) *Cell* **94**, 773–782
 20. Borg, J.-P., Straight, S. W., Kaech, S. M., De Taddéo-Borg, M., Kroon, D. E., Karnak, D., Turner, R. S., Kim, S. K., and Margolis, B. (1998) *J. Biol. Chem.* **273**, 31633–31636
 21. Borg, J. P., Lopez-Figueroa, M. O., De Taddéo-Borg, M., Kroon, D. E., Turner, R. S., Watson, S. J., and Margolis, B. (1999) *J. Neurosci.* **19**, 1307–1316
 22. Okamoto, M., and Sudhof, T. C. (1997) *J. Biol. Chem.* **272**, 31459–31464
 23. Okamoto, M., and Sudhof, T. C. (1998) *Eur. J. Cell Biol.* **77**, 161–165
 24. Ide, N., Hata, Y., Hirao, K., Irie, M., Deguchi, M., Yao, I., Satoh, A., Wada, M., Takahashi, K., Nakanishi, H., and Takai, Y. (1998) *Biochem. Biophys. Res. Commun.* **244**, 258–262
 25. Biederer, T., and Südhof, T. C. (2000) *J. Biol. Chem.* **275**, 39803–39806
 26. Maximov, A., Sudhof, T. C., and Bezprozvanny, I. (1999) *J. Biol. Chem.* **274**, 24453–24456
 27. Setou, M., Nakagawa, T., Seog, D.-H., and Hirokawa, N. (2000) *Science* **288**, 1796–1802
 28. Lau, K.-F., McLoughlin, D. M., Standen, C., and Miller, C. C. J. (2000) *Mol. Cell Neurosci.* **16**, 555–563
 29. McLoughlin, D. M., Standen, C. L., Lau, K.-F., Ackerley, S., Bartnikas, T. P., Gitlin, J. D., and Miller, C. C. J. (2001) *J. Biol. Chem.* **276**, 9303–9307
 30. Biederer, T., Cao, X., Sudhof, T. C., and Liu, X. (2002) *J. Neurosci.* **22**, 7340–7351
 31. Borg, J. P., Yang, Y. N., De Taddéo-Borg, M., Margolis, B., and Turner, R. S. (1998) *J. Biol. Chem.* **273**, 14761–14766
 32. Sastre, M., Turner, R. S., and Levy, E. (1998) *J. Biol. Chem.* **273**, 22351–22357
 33. Ho, C. S., Marinescu, V., Steinhilb, M. L., Gaut, J. R., Turner, R. S., and Stuenkel, E. L. (2002) *J. Biol. Chem.* **277**, 27021–27028
 34. Busciglio, J., Gabuzda, D. H., Matsudaira, P., and Yankner, B. A. (1993) *Proc. Natl. Acad. Sci. U. S. A.* **90**, 2092–2096
 35. Turner, R. S., Suzuki, N., Chyung, A. S. C., Younkin, S. G., and Lee, V. M. Y. (1996) *J. Biol. Chem.* **271**, 8966–8970
 36. Tienari, P. J., Ida, N., Ikonen, E., Simons, M., Weidemann, A., Multhaup, G., Masters, C. L., Dotti, C. G., and Beyreuther, K. (1997) *Proc. Natl. Acad. Sci. U. S. A.* **94**, 4125–4130
 37. Cook, D. G., Forman, M. S., Sung, J. C., Leight, S., Kolson, D. L., Iwatsubo, T., Lee, V. M. Y., and Doms, R. W. (1997) *Nat. Med.* **3**, 1021–1023
 38. Borchelt, D. R., Ratovitski, T., Van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., and Sisodia, S. S. (1997) *Neuron* **19**, 939–945
 39. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F. S., and Cole, G. (1996) *Science* **274**, 99–102
 40. Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., and Younkin, S. G. (2001) *J. Neurosci.* **21**, 372–381
 41. McLoughlin, D. M., Irving, N. G., Brownlees, J., Brion, J.-P., Leroy, K., and Miller, C. C. J. (1999) *Eur. J. Neurosci.* **11**, 1988–1994
 42. Lau, K. F., Howlett, D. R., Kesavapany, S., Standen, C. L., Dingwall, C., McLoughlin, D. M., and Miller, C. C. J. (2002) *Mol. Cell Neurosci.* **20**, 13–20
 43. Kurt, M. A., Davies, D. C., Kidd, M., Duff, K., Rolph, S. C., Jennings, K. H., and Howlett, D. R. (2001) *Exp. Neurol.* **171**, 59–71
 44. Moechars, D., Dewachter, I., Lorent, K., Reverse, D., Baekelandt, V., Naidu, A., Tesseur, I., Spittaels, K., Haute, C. V., Checler, F., Godaux, E., Cordell, B., and Van Leuven, F. (1999) *J. Biol. Chem.* **274**, 6483–6492
 45. Nakajima, Y., Okamoto, M., Nishimura, H., Obata, K., Kitano, H., Sugita, M., and Matsuyama, T. (2001) *Brain Res. Mol. Brain Res.* **92**, 27–42
 46. Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., Sanders, S., Zehr, C., O'Campo, K., Hardy, J., Prada, C. M., Eckman, C., Younkin, S., Hsiao, K., and Duff, K. (1998) *Nat. Med.* **4**, 97–100
 47. Bodendorf, U., Danner, S., Fischer, F., Stefani, M., Sturchler-Pierrat, C., Wiederhold, K. H., Staufenbiel, M., and Paganetti, P. (2002) *J. Neurochem.* **80**, 799–806
 48. Citron, M., Westaway, D., Xia, W. M., Carlson, G., Diehl, T., Levesque, G., Johnson-Wood, K., Lee, M., Seubert, P., Davis, A., Kholodenko, D., Motter, R., Sherrington, R., Perry, B., Yao, H., Strome, R., Lieberburg, I., Rommens, J., Kim, S., Schenk, D., Fraser, P., Hyslop, P. S., and Selkoe, D. J. (1997) *Nature Med.* **3**, 67–72
 49. Dineley, K. T., Xia, X., Bui, D., Sweatt, J. D., and Zheng, H. (2002) *J. Biol. Chem.* **277**, 22768–22780
 50. Duff, K., and Rao, M. V. (2001) *Curr. Opin. Neurol.* **14**, 441–447
 51. Wong, P. C., Cai, H., Borchelt, D. R., and Price, D. L. (2002) *Nat. Neurosci.* **5**, 633–639
 52. Tanahashi, H., and Tabira, T. (1999) *Biochem. Biophys. Res. Commun.* **255**, 663–667
 53. Westerman, M. A., Cooper-Blacketer, D., Mariash, A., Kotilinek, L., Kawarabayashi, T., Younkin, L. H., Carlson, G. A., Younkin, S. G., and Ashe, K. H. (2002) *J. Neurosci.* **22**, 1858–1867
 54. De Strooper, B., Saftig, P., Craessaerts, K., Vandersticheles, H., Guhde, G., Annaert, W., Von Figura, K., and Van Leuven, K. (1998) *Nature* **391**, 387–390
 55. Yu, H. K., Saura, C. A., Choi, S. Y., Sun, L. D., Yang, X. D., Handler, M., Kawarabayashi, T., Younkin, L., Fedele, B., Wilson, M. A., Younkin, S., Kandel, E. R., Kirkwood, A., and Shen, J. (2001) *Neuron* **31**, 713–726
 56. Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., and Selkoe, D. J. (1999) *Nature* **398**, 513–517
 57. Li, Y.-M., Xu, M., Lai, M.-T., Huang, Q., Castro, J. L., DiMuzio-Mower, J., Harrison, T., Lellis, C., Nadin, A., Neduveil, J. G., Register, R. B., Sardana, M. K., Shearman, M. S., Smith, A. L., Shi, X.-P., Yin, K.-C., Shafer, J. A., and Gardell, S. J. (2000) *Nature* **405**, 689–694
 58. Esler, W. P., Kimberly, W. T., Ostaszewski, B. L., Diehl, T. S., Moore, C. L., Tsai, J. Y., Rahmati, T., Xia, W., Selkoe, D. J., and Wolfe, M. S. (2000) *Nat. Cell Biol.* **2**, 428–434
 59. Herreman, A., Serneels, L., Annaert, W., Collen, D., Schoonjans, L., and De Strooper, B. (2000) *Nat. Cell Biol.* **2**, 461–462